GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » 5-Year RORE %

SZLSF (StageZero Life Sciences) 5-Year RORE % : -2.37% (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. StageZero Life Sciences's 5-Year RORE % for the quarter that ended in Jun. 2024 was -2.37%.

The industry rank for StageZero Life Sciences's 5-Year RORE % or its related term are showing as below:

SZLSF's 5-Year RORE % is ranked worse than
50.86% of 175 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.01 vs SZLSF: -2.37

StageZero Life Sciences 5-Year RORE % Historical Data

The historical data trend for StageZero Life Sciences's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences 5-Year RORE % Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.36 -28.85 -34.01 -24.31 -11.34

StageZero Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.94 -25.46 3.20 -4.40 -2.37

Competitive Comparison of StageZero Life Sciences's 5-Year RORE %

For the Diagnostics & Research subindustry, StageZero Life Sciences's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences's 5-Year RORE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's 5-Year RORE % falls into.



StageZero Life Sciences 5-Year RORE % Calculation

StageZero Life Sciences's 5-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.018--0.027 )/( -0.379-0 )
=0.009/-0.379
=-2.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 5-year before.


StageZero Life Sciences  (OTCPK:SZLSF) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


StageZero Life Sciences 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.